Aveanna Healthcare (AVAH) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aveanna Healthcare (AVAH) has outperformed GeneDx (WGS) over the past year, gaining 36.8% versus a loss of 44.8%. Over five years, AVAH leads with a +81.9% price change compared with -73.7% for WGS. Aveanna Healthcare is the larger company by market cap ($2.69 billion vs $2.07 billion), about 1.3 times the size, while GeneDx is growing revenue faster (+40.0% vs +20.2%).
On valuation, Aveanna Healthcare trades at a lower forward P/E (13.6x vs 58.0x for GeneDx). Aveanna Healthcare converts more of its revenue into profit, with a net margin of 9.2% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVAH | WGS |
|---|---|---|
| Share price | $12.31 | $69.47 |
| Market cap | $2.69B | $2.07B |
| 1-day change | +0.57% | +2.57% |
| YTD return | +49.82% | -47.92% |
| 1-year return | +36.76% | -44.80% |
| 5-year return | +81.87% | -73.65% |
| P/E ratio (TTM) | 9.77 | — |
| Forward P/E | 13.56 | 57.96 |
| EPS (TTM) | $1.26 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.43B | $427.54M |
| Revenue growth (YoY) | +20.19% | +39.97% |
| Net income (latest FY) | $225.03M | $-21.02M |
| Gross margin | 33.31% | 69.74% |
| Operating margin | 10.54% | -3.06% |
| Net margin | 9.25% | -4.92% |
| 52-week high | $14.71 | $170.87 |
| 52-week low | $5.93 | $32.21 |
| Distance from 52-week high | -16.31% | -59.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +20.63% | +34.59% |
| Average volume | 3.06M | 730.21K |
| Shares outstanding | 218.29M | 29.82M |
| Employees | 3,500 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVAH has outperformed WGS by 81.6 percentage points over the past year.
- Aveanna Healthcare is more profitable, keeping 9.2 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- GeneDx grew revenue faster in its latest fiscal year (+39.97% vs +20.19%).
About Aveanna Healthcare
AVAH stock →Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.
Health Care · Medical/Nursing Services · 3,500 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
AVAH vs WGS FAQ
Which is bigger, Aveanna Healthcare or GeneDx?
Aveanna Healthcare (AVAH) is larger, with a market capitalization of $2.69B compared with $2.07B for GeneDx (WGS).
Which stock has performed better over the past year, AVAH or WGS?
AVAH returned +36.76% over the past 12 months, compared with -44.80% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are Aveanna Healthcare and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.